Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412880 · ClinicalTrials.gov registry record · Phase 2
BI 2536 Second Line Monotherapy in SCLC
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00412880 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 23 participants.
The verdict
NCT00412880, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.
Interventions
- DRUG BI 2536
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-02-14 |
| Est. Completion | 2008-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412880
The ClinicalTrials.gov registry entry for NCT00412880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 2536 is the first listed.
NCT00412880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412880 about?
NCT00412880 is a clinical study titled "BI 2536 Second Line Monotherapy in SCLC". Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.
What is the current status of trial NCT00412880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2007-02-14. Estimated completion is 2008-06-30.
What interventions are being tested in trial NCT00412880?
The interventions under investigation include: BI 2536 (DRUG).
Who is sponsoring clinical trial NCT00412880?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.